DefiniGEN Revenue and Competitors
Estimated Revenue & Valuation
- DefiniGEN's estimated annual revenue is currently $5.7M per year.
- DefiniGEN's estimated revenue per employee is $155,000
Employee Data
- DefiniGEN has 37 Employees.
- DefiniGEN grew their employee count by 6% last year.
DefiniGEN's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CBO and Executive Director | Reveal Email/Phone |
3 | Marketing Manager | Reveal Email/Phone |
DefiniGEN Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is DefiniGEN?
DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company's key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke's Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments.
keywords:N/A
N/A
Total Funding
37
Number of Employees
$5.7M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 37 | -39% | $60M |
#2 | $4.3M | 37 | 32% | N/A |
#3 | $4.1M | 37 | 16% | N/A |
#4 | $4.1M | 37 | 6% | N/A |
#5 | $6.7M | 37 | -5% | N/A |